Pharmacogenetics of migraine: genetic variants and their potential role in migraine therapy.
Migraine is a paroxysmal neurological disorder affecting up to 6% of males and 18% of females in the general population, and has been demonstrated to have a strong, but complex, genetic component. Genetic investigation of migraine provides hope that new targets for medications and individual specific therapy will be developed. The identification of polymorphisms or genetic biomarkers for disease susceptibility and treatment should aid in providing a better understanding of migraine pathology and, consequently, more appropriate and efficient treatment for migraineurs. In this review, we will discuss results investigating genetic biomarkers for migraine and their potential role in future therapy planning.
Fernandez
F
F
Genomics Research Centre, School of Medical Science, Griffith University, Gold Coast, Queensland, 9726 Australia.
Colson
N J
NJ
Griffiths
L R
LR
D000818:Animals; D014644:Genetic Variation / Q000502:physiology*; D006801:Humans; D008881:Migraine Disorders / Q000235:genetics* / Q000628:therapy*; D009154:Mutation / Q000235:genetics; D010597:Pharmacogenetics / Q000379:methods* / Q000639:trends